Corvus Pharmaceuticals is being revisited after a 25% decline, with its primary drug advancing across multiple indications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback